ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

ICON plc

Icon ( ($ICLR) ) just unveiled an update. ICON plc disclosed that it has delayed filing its Annual Report on Form 20-F for the year ended December ...

ICON Faces Nasdaq Deficiency Notice as It Delays 2025 Annual Report Filing

Icon ( ($ICLR) ) has released a notification of late filing. ICON plc has filed a Form 12b-25, signaling a delay in submitting its Form 20-F (Yearl...

ICON plc Delays Annual 20-F Amid Restatement

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN) and Icon (ICLR). Amgen (AMGN) In a report released y...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Icon (ICLR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NeoGenomics (NEO), CG Oncology, Inc. (CGON) and Icon (ICLR). NeoG...

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), CG Oncology, Inc. (CGON) and Icon (ICLR)

An announcement from Icon ( ($ICLR) ) is now available. On April 27, 2026, ICON plc’s audit committee concluded that investors should no longer rel...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ICLR	$113.85	-2.51%	996.41K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ICLR	$113.85	-2.5%	996.41K
3
4
5
6

ICLR

ICLR

Get ICON plc Data in Excel

Get ICON plc Data in Excel